A Natural History Study of RYR1-Related Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-11

Study Completion Date

2031-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Congenital myopathies (CM) are genetic disorders that can cause decreased muscle tone and muscle weakness. Most CMs in the United States are related to the ryanodine receptor 1 (RYR1) gene. Researchers need more natural history data to learn about these CMs in children and adults.

Objective:

To learn more about the signs, symptoms, and course of RYR1-related disorders.

Eligibility:

People aged 7 years and older with an RYR1-related disorder.

Design:

Ambulatory participants will come to the Clinical Center and non-ambulatory participants will visit via telehealth.

Visits will be once a year for 3 or 5 years. Clinical Center visits will take 2 to 3 days.

All participants will undergo tests including:

Photos and videos. These will be taken to document the participant s condition.

Blood and urine tests.

Activity Tracker. Participants will wear a device to record their activity.

Questionnaires. Participants will answer questions about their health, pain, fatigue, stress, quality of life, and other topics.

Participants who visit the Clinical Center will also undergo:

Tests of heart and lung function.

Motor skills and strength tests. Participants will walk, climb stairs, kneel, crawl, stand up, and perform other movements to test their strength and abilities. They will squeeze and pinch a handheld device to test their grip.

Imaging scans.

Skin biopsy. Adult participants may opt to have a sample of skin taken (one time only).

Eye exam

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Contractile Cross Sectional Areas and Muscle Strength in Patients With Congenital Myopathies

NCT03018184

Inherited Muscle Diseases Congenital Myopathy RYR1-myopathy

COMPLETED

Antioxidant Therapy in RYR1-Related Congenital Myopathy

NCT02362425

Neuromuscular Disease

COMPLETED PHASE1/PHASE2

Contractile Properties of Hypertrofic Muscles in Patients With Non-Dystrophic Myotonia

NCT04799366

Non-Dystrophic Myotonia Myotonia Congenita

COMPLETED

Multicenter Observational Study of Myotonic Dystrophy Type 1

NCT02308657

Myotonic Dystrophy Type 1

COMPLETED

Aerobic Training in Patients With Congenital Myopathies

NCT02020187

Congenital Myopathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

STUDY DESCRIPTION:

This prospective natural history study seeks to characterize the clinical manifestations and course of Ryanodine Receptor 1 -related disorders (RYR1-RD). RYR1-RD include a wide range of rare congenital and adult-onset neuromuscular phenotypes that are typically slowly progressive. The study is observational and comprises a primary data collection phase (Years 1-3) and extended follow-up phase (Years 4-5), stratified into centralized (ambulatory) and decentralized (non-ambulatory) arms. During each phase, there will be one visit per year. The study will enhance the foundational knowledge of RYR1-RD and support clinical trial readiness.

OBJECTIVE:

Primary:

Characterize phenotype and disease course over a three-year period

Secondary:

Characterize phenotype and disease course over an extended (2-year) period (total 5 years)

Exploratory:

1. Investigate potential biomarkers of disease status and progression
2. Explore clinical meaningfulness thresholds for research assessments
3. Extract common data elements from existing medical records (real-world evidence)

ENDPOINTS:

Primary:

Change from baseline to Year 3 in:

Motor function and performance
* Motor Function Measure (MFM) sub-domains (percent of maximum score)
* Six-minute walk test (meters travelled with percent predicted)
* Timed functional tests (ascend four stairs, descend four stairs, supine to stand) (seconds)
* Grip and pinch strength (kg and percent predicted)
* Performance of Upper Limb (PUL)
* Accelerometry (wearable sensor)
* Quantitative muscle assessment
* Brooke and Vignos assessment

Pulmonary function
* Forced vital capacity (percent reference norm)
* Forced expiratory volume at 1 second (percent reference norm)
* Slow vital capacity (Liters)
* Maximal voluntary ventilation (Liters)
* Maximum inspiratory pressure (MIP)
* Maximum expiratory pressure (MEP)

Patient-reported outcomes
* PROMIS-57 Profile (subscale and overall t-scores); adults - depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and satisfaction with participation in social roles
* PROMIS Ped-25 Profile (subscale and overall t-scores); 8 - 17 y
* PROMIS Parent Proxy 25 Profile - Fatigue, physical stress experiences, positive affect and wellbeing, psychological stress experiences, anxiety/fear, physical function, pain; 5 - 7 y
* PROMIS Upper Extremity - Short Form 7a
* PROMIS Pediatric Upper Extremity - Short Form 8a
* PROMIS Parent Proxy Upper Extremity - Short Form 8a
* Physical Activity Questionnaire for Children (PAQ-C); 8 - 13 y
* Physical Activity Questionnaire for Adolescents (PAQ-A); 14 - 17 y
* International physical activity questionnaire (IPAQ); adults

Ophthalmology
* Visual acuity
* Dilated ophthalmology exam at baseline only
* Extraocular motility assessment
* Marginal reflex distance (Ptosis)
* Optical Coherence Tomography
* Ancillary testing, imaging, and repeat dilated exams as indicated, based on assessment and discretion of clinician

Secondary:

Change from baseline to Year 5 in:

Motor function and performance
* Motor Function Measure (MFM) sub-domains (percent of maximum score)
* Six-minute walk test (meters travelled with percent predicted)
* Timed functional tests (ascend four stairs, descend four stairs, supine to stand) (seconds)
* Grip and pinch strength (kg and percent predicted)
* Performance of Upper Limb (PUL)
* Accelerometry (wearable sensor)
* Quantitative muscle assessment
* Brooke and Vignos assessment

Pulmonary function
* Forced vital capacity (percent reference norm)
* Forced expiratory volume at 1 second (percent reference norm)
* Slow vital capacity (Liters)
* Maximal voluntary ventilation (Liters)
* Maximum inspiratory pressure (MIP)
* Maximum expiratory pressure (MEP)

Patient-reported outcomes
* PROMIS-57 Profile (subscale and overall t-scores); adults - depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and satisfaction with participation in social roles
* PROMIS Ped-25 Profile (subscale and overall t-scores); 8 - 17 y
* PROMIS Parent Proxy -25 Profile Fatigue, physical stress experiences, positive affect and wellbeing, psychological stress experiences, anxiety/fear, physical function, pain; 5 - 7 y
* PROMIS Upper Extremity - Short Form 7a
* PROMIS Pediatric Upper Extremity - Short Form 8a
* PROMIS Parent Proxy Upper Extremity - Short Form 8a
* Physical Activity Questionnaire for Children (PAQ-C); 8 - 13 y
* Physical Activity Questionnaire for Adolescents (PAQ-A); 14 - 17 y
* International physical activity questionnaire (IPAQ); adults

Ophthalmology
* Visual acuity
* Dilated ophthalmology exam at baseline only
* Extraocular motility assessment
* Marginal reflex distance (Ptosis)
* Optical Coherence Tomography
* Ancillary testing, imaging, and repeat dilated exams as indicated, based on assessment and discretion of clinician

Exploratory:

Biomarkers

Including but not limited to:
* Plasma NAD plus, NADH
* Plasma GSH, GSSG
* Plasma cytokines
* Serum creatine phosphokinase
* Urine and plasma 15-F2t isoprostane
* Urine 8OHdG
* PBMC (Peripheral Blood Mononuclear Cell)
* Near infrared spectroscopy (muscle tissue oxygenation)
* Dixon MRI of lower extremity
* Optional skin punch biopsy (fibroblast culture)
* Muscle ultrasound
* Electrical impedance myography (EIM)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ryanodine Receptor 1-Related Myopathy Ryanodine Receptor 1 Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Centralized

Visits are conducted at the NIH clinical center. All participants are ambulatory.

No interventions assigned to this group

Decentralized

Visits are conducted via telehealth.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Stated willingness to comply with all study procedures, availability for the duration of the study, and submission of medical records to research team prior to screening.
2. Male or female, aged \>=7 years of age.
3. Genetically confirmed RYR1-related disorder, evidenced by pathogenic or likely pathogenic variants identified by CLIA testing (whole genome, exome, targeted, partial or full RYR1 sequencing) OR variant of uncertain significance with supporting clinical phenotype.
4. Agreement to adhere to Lifestyle Considerations throughout study duration.
5. Ability of subject to communicate their understanding of the purpose of the study, and willingness to provide assent and/or to sign a written informed consent document.
6. Resides in the United States.

1. Stated willingness to comply with all study procedures, availability for the duration of the study, and submission of medical records to research team prior to screening.
2. Male or female, aged \> 7 years of age.
3. Genetically confirmed RYR1-related disorder, evidenced by pathogenic or likely pathogenic variants identified by CLIA testing (whole genome, exome, targeted, partial or full RYR1 sequencing) OR variant of uncertain significance with supporting clinical phenotype.
4. Ability of subject to communicate their understanding of the purpose of the study, and willingness to provide assent and/or sign a written informed consent document.
5. Resides in the United States

Exclusion Criteria

1. Participation in an IND, IDE, or equivalent clinical study in the past six months
2. Severe disability or mobility issues (inability to walk 10 meters with or without assistance)
3. Requires mechanical ventilation or tracheotomy
4. Other neuromuscular diseases resulting in muscle weakness
5. Ongoing medical condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study (e.g. active infection) or safety of the subject.

1. Participation in an IND, IDE, or equivalent clinical study in the past six months
2. Other neuromuscular diseases resulting in muscle weakness
3. Ongoing medical condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study (e.g. active infection) or safety of the subject

Minimum Eligible Age

7 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No